Epoprostenol
"Epoprostenol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY).
| Descriptor ID |
D011464
|
| MeSH Number(s) |
D10.251.355.255.100.637.550.500 D10.251.355.255.550.550.500 D23.469.050.175.725.895.500
|
| Concept/Terms |
Epoprostenol- Epoprostenol
- PGI2
- PGX
- Prostaglandin I2
- Prostacyclin
- Prostaglandin I(2)
- Epoprostanol
Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer- Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer
|
Below are MeSH descriptors whose meaning is more general than "Epoprostenol".
Below are MeSH descriptors whose meaning is more specific than "Epoprostenol".
This graph shows the total number of publications written about "Epoprostenol" by people in UAMS Profiles by year, and whether "Epoprostenol" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2021 | 0 | 1 | 1 |
| 2012 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 1996 | 2 | 0 | 2 |
| 1995 | 3 | 1 | 4 |
| 1994 | 1 | 0 | 1 |
| 1992 | 0 | 1 | 1 |
| 1991 | 1 | 0 | 1 |
| 1990 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Epoprostenol" by people in Profiles over the past ten years.
-
Coleman RD, Chartan CA, Mourani PM. Intensive care management of right ventricular failure and pulmonary hypertension crises. Pediatr Pulmonol. 2021 03; 56(3):636-648.
-
Hutchison MR, White PC. Prostacyclin regulates bone growth via the Epac/Rap1 pathway. Endocrinology. 2015 Feb; 156(2):499-510.